The Life Sciences team advised Collegium Pharmaceutical, Inc. ("Collegium") on a definitive agreement pursuant to which Collegium will acquire AZSTARYS from Corium Therapeutics Holdings, LLC ("Corium Therapeutics") for $650 million in cash with the potential for additional milestone payments up to $135 million depending on future commercial and regulatory milestones. The acquisition of AZSTARYS is expected to significantly strengthen Collegium’s position in ADHD, further diversifying and bolstering its revenue base.
Collegium is building a leading diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by JORNAY PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with JORNAY PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts.
The Goodwin team was led by Jennifer Porter and Stephanie Isaia and included Arman Oruc, Elliot Silver, Dan Karelitz, Sarah Bock, Christina Lewis, Julie Tibbets, Dustin Schaefer, Heath Roosevelt Ingram, Katie Cheng, David Chen, Ai Tajima, Jacqueline Klosek, Alice Choi, Julia Novick, Daniela Sanchez, Fiona Aromando, Krupa Zachariah, Shlomo Gottesman, Ana Victoria Alvarado, and Alexandra Bargoot.
For more information on the deal, please read the press release.